| Product Name |
Aprepitant-d4
|
| Product Code |
DA-A280-19
|
| Chemical name |
Aprepitant-d4
|
| Synonyms |
5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl-d4)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; Emend-d4; L 754030-d4; MK 0869-d4; MK 869-d4; ONO 7436-d4;
|
| Impurity |
NA
|
| CAS Number |
1133387-60-6
|
| Alternate CAS # |
NA
|
| Molecular form |
C23H17D4F7N4O3
|
| Appearance |
White Solid
|
| Melting Point |
NA
|
| Mol. Weight |
538.45
|
| Storage |
2-8°C Refrigerator
|
| Solubility |
NA
|
| Stability |
NA
|
| Category |
chiral standards,heterocycles,pharmaceutical standards,intermediates,fine chemicals,stable isotopes
|
| Boiling Point |
NA
|
| Applications |
Aprepitant-d4 is a labeled analogue of Aprepitant, A novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Aprepitant-d4 is a potential treatment for chemotherapy induced nausea and vomiting.
|
| Dangerous Goods Info |
NA
|
| References |
NA
|
| Extra Notes |
NA
|
| Documents (MSDS) |
No Data Available
|
| Keywords |
NA |
